Merck & Co., Inc.

🇺🇸New York Stock Exchange
Back to all articles
Merck & Co., Inc. stock analysis MRK overview
Bullish +75

Merck & Co., Inc. $MRK Shares Acquired by Diamant Asset Management Inc.

📈 Diamant Asset Management Inc. boosted its MRK stake by 12,130.3% in Q1, adding 2,051,475 shares to reach a total holding of 2,068,387 shares.

💰 Merck reported Q1 revenue of $16.29 billion, beating consensus estimates of $15.85 billion by $0.44 billion.

📊 The company posted an EPS of $1.28, significantly beating the analyst consensus estimate of a loss of ($1.47).

🚀 Revenue grew 4.9% year-over-year to $16.29 billion, demonstrating solid top-line growth.

💵 Merck announced a quarterly dividend of $0.85 per share with an annualized yield of 2.6%.

📅 The company has set FY 2026 EPS guidance between $5.04 and $5.16, aligning with analyst expectations.

🏥 Keytruda and Gardasil remain central to the portfolio in oncology and vaccines respectively.

📉 Institutional ownership stands at 76.07%, indicating strong confidence from large investors.

📈 The stock trades at a P/E ratio of 36.15 with a market cap of $316.99 billion.

Bullish Signals
  • Merck beat Q1 earnings estimates significantly, reporting an EPS of $1.28 versus a consensus loss of ($1.47).
  • Revenue increased 4.9% year-over-year to $16.29 billion, exceeding analyst expectations of $15.85 billion.
  • Diamant Asset Management Inc. executed a massive stake increase, buying over 2 million shares in Q1.
  • The company maintains a healthy balance sheet with a current ratio of 1.30 and quick ratio of 1.06.
  • Merck provides a consistent dividend yield of 2.6% to shareholders.
Full Analysis
Diamant Asset Management Inc. significantly increased its stake in Merck & Co., Inc. (NYSE:MRK) by over 12,000% in the first quarter, purchasing an additional 2.05 million shares to hold a total of 2.07 million shares. This position represents 0.8% of Diamant's portfolio and is valued at approximately $248.8 million based on recent filings. Several other smaller institutional investors also established or increased positions in the stock during the third and fourth quarters, while hedge funds collectively own roughly 76% of the company's outstanding shares. Merck reported strong quarterly financial results ending April 30th, with revenue reaching $16.29 billion, a 4.9% year-over-year increase that beat analyst consensus estimates. The company posted an earnings per share (EPS) of $1.28, surpassing the expected loss of $1.47, and achieved a net margin of 13.59%. Management has provided fiscal 2026 guidance for EPS between $5.04 and $5.16, which aligns closely with the average analyst prediction of $5.17. The biopharmaceutical giant continues to distribute capital to shareholders through a quarterly dividend of $0.85 per share, payable on July 8th for stockholders of record as of June 15th. This results in an annualized dividend yield of 2.6% and a payout ratio of 95.77%. The company maintains a robust balance sheet with a market capitalization of $316.99 billion and operates key products including the cancer immunotherapy Keytruda and the HPV vaccine Gardasil.